Literature DB >> 24583564

Candidemia: incidence rates, type of species, and risk factors at a tertiary care academic hospital in China.

Zengbin Wu1, Yingbin Liu2, Xiaobo Feng3, Ying Liu4, Shuyun Wang1, Xiaodong Zhu5, Qiqi Chen1, Shuming Pan6.   

Abstract

OBJECTIVES: To investigate the incidence rates of candidemia in hospitalized patients and to identify differences in risk factors of patients with Candida albicans and non-C. albicans and with Candida guilliermondii and non-C. guilliermondii candidemia.
METHODS: Non-immunosuppressed, non-neutropenic inpatients with candidemia diagnosed after admission were included in this retrospective observational study at a tertiary academic hospital in China.
RESULTS: During the study period (January 2009 to December 2011), 238 eligible patients had candidemia episodes with an incidence rate 5.4%. Of these patients, 29.8% had candidemia due to C. albicans, 27.7% due to C. parapsilosis, and 16.4% due to C. guilliermondii. Diabetes was a significant risk factor for patients with candidemia due to C. albicans (35.2%, 25/71) compared to candidemia due to non-C. albicans spp (13.2%, 22/167) (odds ratio (OR) 0.2792, 95% confidence interval (CI) 0.144-0.5412; p < 0.001). Compared to patients with candidemia due to non-C. guilliermondii spp, preterm birth with low birth weight (OR 0.0887, 95% CI 0.0398-0.1977; p < 0.001), intravenous nutrition (OR 0.0662, 95% CI 0.0226-0.1938), and surgery (OR 0.0662, 95% CI 0.0226-0.1938; p < 0.001) were significant risk factors for candidemia due to C. guilliermondii. Furthermore, compared to patients with candidemia due to C. albicans, patients with candidemia due to C. guilliermondii had markedly higher rates of central venous catheterization (85.9%, 61/71 vs. C. guilliermondii: 100%, 39/39; p = 0.013) and intravenous nutrition (89.7%, 35/39 vs. C. albicans: 42.2%, 30/71; p < 0.001).
CONCLUSIONS: Candidemia due to C. albicans ranks first in incidence, and candidemia due to C. guilliermondii occurs in a significant proportion of our hospitalized patients.
Copyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Candid albicans; Candida guilliermondii; Candidemia; Incidence

Mesh:

Year:  2014        PMID: 24583564     DOI: 10.1016/j.ijid.2013.11.011

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  20 in total

1.  Candida fermentati as a cause of persistent fungemia in a preterm neonate successfully treated by combination therapy with amphotericin B and caspofungin.

Authors:  Noura Al-Sweih; Suhail Ahmad; Leena Joseph; Seema Khan; Sandhya Vayalil; Rachel Chandy; Ziauddin Khan
Journal:  J Clin Microbiol       Date:  2015-01-07       Impact factor: 5.948

2.  Clinical and microbiological investigation of fungemia from four hospitals in China.

Authors:  Danfeng Dong; Zhen Li; Lihua Zhang; Cen Jiang; Enqiang Mao; Xuefeng Wang; Yibing Peng
Journal:  Mycopathologia       Date:  2015-02-27       Impact factor: 2.574

3.  Development of two molecular approaches for differentiation of clinically relevant yeast species closely related to Candida guilliermondii and Candida famata.

Authors:  Xiaobo Feng; Jingsong Wu; Bo Ling; Xianwei Yang; Wanqing Liao; Weihua Pan; Zhirong Yao
Journal:  J Clin Microbiol       Date:  2014-06-20       Impact factor: 5.948

4.  Inhibition of nucleic acid biosynthesis makes little difference to formation of amphotericin B-tolerant persisters in Candida albicans biofilm.

Authors:  Jing Sun; Xiaohua Liu; Guangshui Jiang; Qingguo Qi
Journal:  Antimicrob Agents Chemother       Date:  2014-12-29       Impact factor: 5.191

5.  Candidaemia observed at a university hospital in Milan (northern Italy) and review of published studies from 2010 to 2014.

Authors:  Laura Milazzo; Anna Maria Peri; Cristina Mazzali; Romualdo Grande; Chiara Cazzani; Davide Ricaboni; Antonio Castelli; Ferdinando Raimondi; Carlo Magni; Massimo Galli; Spinello Antinori
Journal:  Mycopathologia       Date:  2014-07-24       Impact factor: 2.574

6.  Species distribution and in vitro antifungal susceptibility profiles of yeast isolates from invasive infections during a Portuguese multicenter survey.

Authors:  I Faria-Ramos; J Neves-Maia; E Ricardo; J Santos-Antunes; A T Silva; S Costa-de-Oliveira; E Cantón; A G Rodrigues; C Pina-Vaz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-07-11       Impact factor: 3.267

Review 7.  Epidemiology of fungal infections in China.

Authors:  Min Chen; Yuan Xu; Nan Hong; Yali Yang; Wenzhi Lei; Lin Du; Jingjun Zhao; Xia Lei; Lin Xiong; Langqi Cai; Hui Xu; Weihua Pan; Wanqing Liao
Journal:  Front Med       Date:  2018-01-11       Impact factor: 4.592

8.  Fluconazole and Voriconazole Resistance in Candida parapsilosis Is Conferred by Gain-of-Function Mutations in MRR1 Transcription Factor Gene.

Authors:  Joana Branco; Ana P Silva; Raquel M Silva; Ana Silva-Dias; Cidália Pina-Vaz; Geraldine Butler; Acácio G Rodrigues; Isabel M Miranda
Journal:  Antimicrob Agents Chemother       Date:  2015-07-27       Impact factor: 5.191

9.  Clinical and therapeutic aspects of candidemia: a five year single centre study.

Authors:  Matteo Bassetti; Maria Merelli; Filippo Ansaldi; Daniela de Florentiis; Assunta Sartor; Claudio Scarparo; Astrid Callegari; Elda Righi
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

10.  Risk Factors for Mortality in Colombian Patients with Candidemia.

Authors:  Jorge Alberto Cortés; Anita María Montañez; Ana María Carreño-Gutiérrez; Patricia Reyes; Carlos Hernando Gómez; Angela Pescador; Beatriz Ariza; Fernando Rosso
Journal:  J Fungi (Basel)       Date:  2021-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.